Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | SPTLC1 | O15269 | 1/20 | 0.47 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980074 | 1.00 | DGKA (0.49) | DGKAFAAHSPTLC1SPTLC2DEGS1 | |
| SCHEMBL29100618 | 0.96 | DGKA (0.52) | DGKAFAAHDEGS1TERTPTPN1 | |
| SCHEMBL2460922 | 0.96 | DGKA (0.52) | DGKAFAAHDEGS1TERTPTPN1 | |
| SCHEMBL26980506 | 0.92 | KMT2A (0.43) | MAPTKMT2ALMNADUSP3MEN1 | |
| SCHEMBL26980322 | 0.92 | KMT2A (0.43) | MAPTKMT2ALMNADUSP3MEN1 | |
| SCHEMBL26980812 | 0.92 | KMT2A (0.43) | MAPTKMT2ALMNADUSP3MEN1 | |
| SCHEMBL26980291 | 0.92 | KMT2A (0.43) | MAPTKMT2ALMNADUSP3MEN1 | |
| SCHEMBL29100634 | 0.88 | CES2 (0.46) | MAPTKMT2ALMNADUSP3MEN1 | |
| SCHEMBL29100688 | 0.88 | CES2 (0.46) | MAPTKMT2ALMNADUSP3MEN1 | |
| SCHEMBL29100664 | 0.88 | CES2 (0.46) | MAPTKMT2ALMNADUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094027-A1 | BLOCKING SEQUENCE, KIT THEREOF, AND METHOD FOR USING SAME | 深圳鸿生生物科技有限公司 | 2024-05-10 | — | — | WO | claimed |
| EP-4297743-A1 | EMULSION FOR USE IN THE TREATMENT OF ROSACEA | Exinov (FR) | 2024-01-03 | — | — | EP | claimed |
| CN-106469251-B | System for evaluating antibacterial power of antibacterial peptide and using method thereof | 杨立威 | 2019-05-14 | — | — | CN | claimed |
| US-20170061288-A1 | EVALUATION SYSTEM FOR THE EFFICACY OF ANTIMICROBIAL PEPTIDES AND THE USE THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2017-03-02 | — | — | US | claimed |
| CN-106469251-A | System for evaluating antibacterial power of antibacterial peptide and using method thereof | 杨立威 | 2017-03-01 | — | — | CN | claimed |
| WO-1996030051-A1 | USE OF SURFACTANTS FOR INTRODUCING GENETIC MATERIAL INTO LUNG CELLS | GENETIC THERAPY, INC. (US) | 1996-10-03 | — | — | WO | claimed |
| WO-2024094027-A1 | BLOCKING SEQUENCE, KIT THEREOF, AND METHOD FOR USING SAME | 深圳鸿生生物科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| US-20240108685-A1 | ORAL LIPOSOMAL COMPOSITIONS | RENAULT JEAN YVES (FR) | 2024-04-04 | — | — | US | disclosed |
| EP-4297743-A1 | EMULSION FOR USE IN THE TREATMENT OF ROSACEA | Exinov (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-4284332-A1 | ORAL LIPOSOMAL COMPOSITIONS | Renault, Jean-Yves (FR) | 2023-12-06 | — | — | EP | disclosed |
| CN-114555127-A | Method for preparing polyglutamated antifolates and use of compositions thereof | L.E.A.F.控股集团公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114026228-A | Optimization of engineered meganucleases for recognition sequences | 精密生物科学公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3374378-B1 | CHARGE-REVERSED N-TERMINAL SPIDER SILK PROTEIN DOMAIN AND USES THEREOF | SPIBER TECH AB (SE) | 2021-02-17 | — | — | EP | disclosed |
| US-10810329-B2 | In silico design of peptides equilibrated in a lipid bilayer with partition free energies indicating probability of antimicrobial activity | NATIONAL TSING HUA UNIVERSITY (TW) | 2020-10-20 | — | — | US | disclosed |
| EP-3374378-A1 | CHARGE-REVERSED N-TERMINAL SPIDER SILK PROTEIN DOMAIN AND USES THEREOF | Spiber Technologies AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081239-A1 | CHARGE-REVERSED N-TERMINAL SPIDER SILK PROTEIN DOMAIN AND USES THEREOF | SPIBER TECHNOLOGIES AB (SE) | 2017-05-18 | — | — | WO | disclosed |
| EP-3168228-A1 | CHARGE-REVERSED N-TERMINAL SPIDER SILK PROTEIN DOMAIN AND USES THEREOF | Spiber Technologies AB (SE) | 2017-05-17 | — | — | EP | disclosed |
| US-20170061288-A1 | EVALUATION SYSTEM FOR THE EFFICACY OF ANTIMICROBIAL PEPTIDES AND THE USE THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2017-03-02 | — | — | US | disclosed |
| US-20100178658-A1 | SCREENING ASSAYS FOR INHIBITORS OF BETA AMYLOID PEPTIDE ION CHANNEL FORMATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2008150467-A1 | SCREENING ASSAYS FOR INHIBITORS OF BETA AMYLOID PEPTIDE ION CHANNEL FORMATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108685-A1 | ORAL LIPOSOMAL COMPOSITIONS | SGMS1, SGMS2, CD14 | DGKA 832/4885FAAH 530/4885SPTLC1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.